Skip to main content

Table 2 Prediction accuracy of DR_SEQAN in comparison with other publicly available algorithms.

From: DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes

Inhibitor

Total no. of isolates

No. of drug-susceptible isolatesa

Percentage of drug-susceptible isolates correctly predicted by the algorithms

   

DR_SEQAN

Retrogram

ANRS

HIVDB

RegaInst

Zidovudine (AZT)

135

48

79.2

64.6

72.9

68.8

72.9

Zalcitabine (ddC)

130

106

83.0

18.9

n.d.b

n.d.

24.5

Didanosine (ddI)

136

104

93.3

20.2

79.8

28.8

27.9

Lamivudine (3TC)

138

59

83.1

79.7

88.1

78.0

78.0

Stavudine (d4T)

136

85

60.0

38.8

41.2

37.6

67.1

Abacavir (ABC)

134

75

88.0

32.0

89.3

38.7

33.3

Nevirapine (NVP)

183

66

87.9

65.2

93.9

90.9

72.7

Delavirdine (DLV)

183

103

83.5

57.3

n.d.

82.5

58.3

Efavirenz (EFV)

180

97

79.4

48.5

67.0

64.9

49.5

Saquinavir (SQV)

548

278

65.8

73.4

89.9

73.4

80.9

Ritonavir (RTV)

510

237

67.9

75.1

84.0

88.6

77.2

Indinavir (IDV)

529

250

70.8

70.0

79.2

78.0

84.0

Nelfinavir (NFV)

567

224

66.1

70.5

80.4

73.7

77.7

Amprenavir (APV)

527

282

72.0

67.7

99.3

70.9

86.9

Lopinavir (LPV)

203

42 (99)

85.7 (43.4)

88.1 (60.6)

100 (87.9)

69.0 (29.3)

81.0 (45.5)

  1. a Drug susceptible isolates were defined as those that in comparison with the wild-type reference clone showed a fold-increase of the IC50 value for each drug, which was below 1.8-fold for AZT, 2.6-fold for ddC, 2-fold for ddI and d4T, 9-fold for 3TC, 4.5-fold for ABC, 6-fold for NVP, DLV and EFV, 1.7-fold for SQV and LPV, 2.5-fold for RTV and IDV, 3.6-fold for NFV and 2-fold for APV. Those cut-off values were consistent with those previously defined for the PhenoSense™ assay [24]. In the case of LPV, the values shown between parenthesis refer to the clinically relevant cut-off value of 10-fold [24].
  2. b n.d., not determined